What Evidence Do Payers Require? 6 Levels Explained

Payers weight one evidence type above all the others: proof that your product moves a cost or outcome they are already accountable for, measured in a way their own analysts can defend internally. Usage data, single-site pilots, and case studies matter — but mainly as steps toward that one artifact: a comparative or economic result tied to a population they actually cover.

Quick Answer: Payers weigh six evidence types, roughly in ascending order of what they unlock: usage data, single-arm pilot outcomes, real-world evidence at scale, comparative or controlled outcomes, peer-reviewed publication, and an independent health-economic model. Real-world evidence is the practical floor for a serious conversation; publication and an economic model are usually what get a contract signed. Exact thresholds vary by payer — confirm yours directly rather than assuming.

Most digital health founders learn the hard way that a payer conversation is not one meeting — it is a review process with its own internal logic, and that logic runs almost entirely on evidence, not on product demos. This guide breaks down the six evidence types payers actually weigh, in the order they typically compound, so you can see where you stand and what the next rung costs before you commit budget to it.

It builds on the broader evidence-ladder framework in clinical evidence for digital health; this piece narrows the lens specifically to what payers, as a buyer class, tend to require before they move from "interesting" to "covered."

Selection criteria: how payer evidence review actually works

Payer evidence review typically runs through three internal layers before a product reaches a covered benefit or a signed contract, and each layer asks a different question.

• Medical or clinical policy review — an internal team, sometimes informed by outside health-technology-assessment research, asks whether the product is safe, does what it claims, and meets the payer's internal evidentiary bar for that category.
• Financial or actuarial review — a separate question entirely: even if this works, does covering it save money, cost money responsibly, or blow up the trend line the actuaries are managing.
• Operational fit — how the product gets coded, billed, and administered inside the payer's existing claims and utilization-management systems, a mechanical question covered in depth in how healthcare reimbursement actually works.

Understanding these layers matters more than memorizing any one requirement, because requirements shift by payer, plan type, and year, while the layers themselves stay structurally stable.

A few other patterns hold across payer types even though exact thresholds do not:

• Bigger populations demand stronger evidence. A regional plan covering a narrow employer group may accept a smaller evidence package than a national payer setting policy for millions of lives.
• Novel categories face a higher bar than established ones. A digital therapeutic with no real precedent gets scrutinized harder than a tool that resembles something already covered.
• Cost-avoidance claims get audited hardest. "This reduces downstream spend" is the claim payers most want to believe and most rigorously try to disprove, because it is also the easiest claim to overstate.
• Nobody discloses their full internal rubric. Published medical policy explains outcomes; it rarely explains the exact evidence bar an internal committee applied to reach them.

That last point is the practical takeaway: treat any specific evidence threshold you hear secondhand — "they need an RCT," "n=500 is the minimum" — as anecdote, not policy. Confirm directly with your target payer's medical policy or market-access contacts, and bring in a market-access specialist once conversations get serious. General playbooks compress; your specific payer's rubric does not.

Level 1: Usage and engagement data

Verdict: necessary, never sufficient — the floor beneath every other level.

Usage and engagement data — activation rate, retention, session frequency — proves people actually use what you built. It is the cheapest evidence you will ever generate, because your own product instrumentation produces it as a byproduct of running the business, not as a separate research effort.

Payers do not reimburse based on engagement alone, but a product with poor real-world engagement fails every level above this one before it even gets evaluated — a strong outcome study on a product nobody uses does not survive contact with an actuary asking about actual utilization. Treat engagement data as a prerequisite you clear quietly, not a pitch you lead with.

Level 2: Single-arm pilot and pre-post outcome data

Verdict: opens conversations; does not close deals.

A single-arm pilot measures a group before and after using your product and reports the change. It is fast, relatively cheap, and genuinely useful for opening a market-access conversation or securing a small pilot contract — payers will take a meeting on a clean pre-post signal that they would not take on engagement data alone.

Its ceiling is well understood on both sides of the table: without a comparison group, you cannot rule out that something other than your product drove the improvement — regression to the mean, seasonality, or simply the attention that comes with being studied. A payer's actuarial team will raise this immediately, so present pilot data as the signal that justified the next, larger study, not as proof on its own.

Level 3: Real-world evidence from production usage

Verdict: the practical floor for a serious payer conversation.

Real-world evidence draws on data from actual deployed use at scale — engagement, outcomes, and utilization across a real population, not a controlled pilot cohort. For many payers, particularly ones deciding whether to expand an existing pilot into a broader benefit, well-instrumented real-world evidence carries more weight than a small, tightly controlled trial, because it reflects the messy population the payer will actually be covering.

The tradeoff is rigor. Production data is self-selected and easy to interpret favorably if you're not careful, so treat it with the same discipline as a formal study: pre-specify your outcome metrics before you look at the data, define your population precisely, and report the full denominator — including the people who dropped off — not just the success stories. A payer's analysts will ask for the denominator whether or not you volunteer it.

Level 4: Comparative or controlled outcomes

Verdict: the point where "it helped" becomes "it helped more than the alternative."

A comparative study adds a comparison group — a matched cohort, a waitlist, or a comparison against standard care — so improvement can be attributed to your product rather than to time or attention. This is where your claim shifts from directional to causal-adjacent, and it is frequently the evidence tier that moves a payer from a pilot mindset into an actual coverage-policy discussion.

You do not necessarily need a full randomized trial to reach this level. A well-matched cohort comparison, done rigorously and pre-registered where possible, often satisfies a payer's medical-policy team for a defined, lower-risk category. Save the full randomized design for claims where the stakes, and the scrutiny, are highest.

Level 5: Peer-reviewed publication

Verdict: converts your data into something a payer's own committee can cite without taking your word for it.

Peer review puts your study design and results in front of independent experts before publication, and that independent scrutiny is what makes the result citable inside someone else's decision process. A payer's medical-policy committee can reference a published, peer-reviewed study in its own documentation in a way it generally cannot reference an internal white paper you wrote yourself, no matter how rigorous that white paper actually is.

Publication is slow — often a year or more from submission to print — so plan for that lag well before the payer conversation where you'll need it. It is also not free-standing: publication documents evidence you already generated at Level 3 or Level 4; it does not substitute for having generated a controlled result in the first place.

Level 6: Independent health-economic model

Verdict: the artifact that actually gets a benefit decision or a contract signed.

A health-economic model translates your clinical or utilization outcomes into the currency a payer's finance function actually transacts in: cost per outcome, budget impact over a defined population and time horizon, or a formal cost-effectiveness estimate. This is the step that answers the actuarial-review question directly instead of leaving the payer's own team to estimate it themselves, which they will do conservatively if you don't do it for them.

Good practice here follows established methodology rather than a bespoke spreadsheet — the budget-impact-analysis good-practice guidance published by ISPOR (the International Society for Pharmacoeconomics and Outcomes Research) is a widely recognized reference point for structuring this kind of model credibly. Commission this from a health economist, ideally one independent of your company, once you have Level 3 or Level 4 outcomes data solid enough to model — a model built on weak inputs just produces a confidently wrong number.

Comparison table: evidence level, cost to produce, and payer weight

The table below lines up all six levels against roughly what they cost to produce and how much weight a payer typically assigns them, so you can see at a glance where additional investment actually moves a coverage decision.

Two patterns stand out. First, cost and payer weight rise together almost the entire way up the table — there is no cheap shortcut to the evidence that actually closes a payer deal. Second, each level depends on the one below it: a health-economic model built on shaky outcomes data is just a confident-looking spreadsheet, so skipping levels to save time usually costs more time later, when a payer's team asks a question your foundation can't answer.

Building toward payer-grade evidence without wasting a round

Sequence this ladder the same way you would sequence any other capital-intensive workstream: generate the minimum evidence that unlocks your next real conversation, not the maximum evidence a journal would accept. That is the same sequencing discipline behind validating demand before you build, laid out more generally in the complete guide to startup idea validation — evidence generation is one workstream competing with product and go-to-market for the same limited runway, and it deserves the same discipline.

Two moves keep this affordable:

• Start the payer conversation earlier than the evidence feels ready for. Market-access and medical-policy contacts will often tell you, directly, what their internal process actually weighs — information no public playbook, including this one, can give you with precision.
• Treat Levels 5 and 6 as commissioned work, not DIY projects. A statistician for peer review and a health economist for the economic model are specialists for a reason; the credibility of both artifacts depends partly on who built them, not just what they say.

Key Takeaways

• One evidence type dominates payer decisions: a cost or outcome result tied to a population the payer covers, expressed in terms their finance function can defend internally.
• Payer evidence review runs through layers, not one gate — clinical/medical policy, financial/actuarial, and operational fit each ask a different question and can each stall a deal independently.
• Real-world evidence at scale is the practical floor for a serious conversation; usage data alone only clears a prerequisite and never closes anything by itself.
• Comparative evidence is where attribution starts — it's the tier that typically shifts a payer from pilot thinking to a coverage-policy discussion.
• Publication and a health-economic model are what actually get signed off — publication for independent credibility, the economic model for speaking the actuary's own language.
• Never treat a secondhand evidence threshold as policy. Confirm requirements directly with your target payer and involve a market-access specialist once conversations get serious.
• Cost and payer weight rise together up the ladder, and each level depends on the one below it — skipping levels to save time usually costs more time later.

Frequently Asked Questions

What evidence do payers require before covering a digital health product?

There is no single universal requirement — it varies by payer, plan type, and category. In general, payers expect real-world evidence at scale as a practical floor, and most serious coverage or contract decisions additionally require comparative or controlled outcomes plus some form of cost or economic justification. Confirm the specific bar with your target payer's medical-policy or market-access team rather than assuming a generic standard applies.

How long does it take to build evidence a payer will actually accept?

It depends heavily on which levels you still need. A real-world evidence package from an existing deployment can sometimes be assembled in months if your instrumentation is already clean. Comparative studies and peer-reviewed publication typically add a year or more, since publication timelines alone often run long. Budget backward from your funding runway, and start payer conversations before every level is finished — payers will often tell you which levels actually matter for your case.

Do payers require randomized controlled trials for digital health products?

Not universally. Many payers will move forward on strong real-world evidence plus a well-matched comparative study, especially for lower-risk categories, without requiring a full randomized controlled trial. Higher-risk therapeutic claims, novel categories, or larger population commitments raise the likelihood a payer's medical-policy team asks for randomized evidence. Ask your specific target payer rather than assuming either extreme.

What is a health-economic model, and does every startup need one?

A health-economic model translates clinical or utilization outcomes into cost-per-outcome or budget-impact terms a payer's finance function can evaluate directly. Not every early-stage conversation needs one — a pilot or a first coverage discussion may proceed on outcomes evidence alone — but it typically becomes necessary once you're negotiating broader coverage or a value-based contract, where the payer needs the financial case made explicit rather than implied.